ARS Pharmaceuticals offers asymmetric upside as neffy attempts to redefine anaphylaxis care, but the thesis depends on rapid commercial execution before cash burn, payer friction, litigation, or new needle-free rivals narrow the opportunity.
Overview
ARS Pharmaceuticals is transforming emergency allergy treatment with neffy, the first FDA- and EU-approved needle-free epinephrine nasal spray. The company is now commercial-stage, generating Q1 2026 revenue of $22.7 million, including $17.5 million in U.S. neffy sales. Strategic partnerships with ALK and Pediatrix expand global reach, while schools, patients, and physicians are drawn to neffy’s portability, 30-month shelf life, temperature stability, and needle-free ease of use.